Compare SAIA & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIA | TGTX |
|---|---|---|
| Founded | 1924 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.5B |
| IPO Year | 2002 | 2008 |
| Metric | SAIA | TGTX |
|---|---|---|
| Price | $341.66 | $64.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 7 |
| Target Price | ★ $414.67 | $77.50 |
| AVG Volume (30 Days) | 372.2K | ★ 1.9M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 8.79 | 0.52 |
| Revenue | ★ $3,234,286,000.00 | $2,785,000.00 |
| Revenue This Year | $13.49 | $61.95 |
| Revenue Next Year | $8.24 | $35.55 |
| P/E Ratio | ★ $37.74 | $124.76 |
| Revenue Growth | ★ 0.79 | N/A |
| 52 Week Low | $249.32 | $26.76 |
| 52 Week High | $494.71 | $68.03 |
| Indicator | SAIA | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 64.72 |
| Support Level | $321.37 | $51.70 |
| Resistance Level | $357.33 | N/A |
| Average True Range (ATR) | 15.40 | 3.49 |
| MACD | -0.37 | 0.65 |
| Stochastic Oscillator | 44.60 | 73.78 |
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 210 facilities and a fleet of more than 7,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.